Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients.

As Veloxis is focussing its efforts and resources on the regulatory approval and commercialisation of Envarsus®, the company is discontinuing future efforts to identify partners for its existing pipeline cardiovascular assets.